Blog

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / COP 29 came and went like the 28 before it: speeches polished to perfection, headlines filled with urgency, and an outcome that changed almost nothing. Three decades of summits and still the world burns plastics instead of recycling them, still accepts fire-safety claims that collapse under pressure, and still mistakes diplomacy for progress.

The UN Plastics Treaty conferences have followed the same pattern. Intent has never been the issue. Nations arrive with lofty goals, banners of ambition, and carefully worded declarations. But years of negotiations have delivered the same story arc: bold frameworks that wither under pressure, vague targets that slip quietly off the agenda, and another round of meetings scheduled to “finalize” what was supposed to be settled long ago. The intent deserves praise. The outcomes deserve scrutiny.

That is why SMX (NASDAQ:SMX) matters. Where diplomacy has stalled, SMX brings enforcement at the molecular level. Its technology embeds proof directly into materials, transforming promises into verifiable results and making sustainability measurable, enforceable, and trusted across borders.

The difference comes down to language. Diplomacy speaks in pledges, policies, and position papers. SMX speaks in proof. One can be debated. The other can be scanned. And in a world drowning in broken promises, only proof can cut through the noise.

Diplomacy Requires A Universal Language of Proof
The uncomfortable truth is this: diplomacy has had its chance. Nearly thirty years of it. The language has evolved, the communiqués have lengthened, and the photo ops have multiplied. However, emissions continue to rise, plastics accumulate, and real-world safety disasters persist, underscoring that promises are no substitute for proof.

Diplomacy falters because consensus is fragile. Every nation arrives with different priorities, and every delegate guards their own interests; the result is watered-down targets that no one can measure or enforce. Policy by negotiation always collapses on contact with reality.

Technology, by contrast, is universal. A molecular marker embedded into plastic in Singapore works the same way in Sweden, South Korea, or São Paulo. A scan confirming flame-retardant safety in Canada is identical to one in California. Proof doesn’t care about borders, politics, or bargaining positions. It is the one language every regulator, insurer, manufacturer, and consumer can understand.

That’s why SMX’s system is so disruptive. It creates clarity where negotiation creates fog. Every recycled material, every under-the-radar plastic, every safety claim is no longer a matter of debate but a matter of fact.

From Ballrooms to Factory Floors
The futility of COP 29 and the UN Plastics Treaty wasn’t just their failure to achieve consensus; it was the spectacle of it all. Delegates fly in, luxury hotels are booked, gala dinners are staged – and then the same empty pledges are recycled alongside the plastics they never manage to regulate. The problem is not a lack of ambition; it is the absence of enforcement.

SMX bypasses that cycle entirely. In Singapore, its work with A*STAR is turning national policy into an enforceable reality through a plastics passport platform. In Europe, its planned partnership with REDWAVE brings verification to the factory floor, where compliance is measured continuously in real-time. And in North America, with NAFRA, flame-retardant safety is finally shifting from datasheets to molecular scans.

This is how change actually scales. Not through press releases at the close of conferences, but through tools embedded in production lines, products, and supply chains. Technology is enforcement. Enforcement is trust. And trust is the foundation of functioning markets.

The End of Negotiated Sustainability
The era of negotiated sustainability is over. It has been tried, and it has failed. What COP 29 and the UN Plastics Treaty proved, if nothing else, is that words alone cannot change the physics of plastics, the chemistry of fire, or the economics of waste. Those realities yield only to technology that works at the level where the problems exist: inside the materials themselves.

SMX represents that shift. It isn’t another pledge, another target, or another diplomatic declaration. It is a platform where governments can regulate with certainty, industries can operate with confidence, insurers can price risk accurately, and consumers can trust the products in their hands.

Diplomacy was supposed to deliver that. It never did. Technology just did.

And history will not remember the meals in Paris, Geneva, or Dubai. It will remember the moment sustainability stopped being negotiated and started being proven – molecule by molecule.

About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States

SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company’s novel crofelemer powder for oral solution for use in two expanded access programs, authorized by the U.S. Food and Drug Administration (FDA), to treat pediatric intestinal failure patients with microvillus inclusion disease (MVID).

“Napo is committed to providing the novel crofelemer formulation as an investigational drug as deemed medically necessary by the physician caregiver for these two patients, intended for mitigating the sequela from MVID disease progression,” said Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board. “We wish both pediatric patients the best outcome and we are grateful to have this collaboration with the patients’ physician.”

Jaguar, through Jaguar family companies Napo and Napo Therapeutics, is currently supporting two independent proof-of-concept investigator-initiated trials (IIT), and conducting two placebo-controlled clinical studies, of crofelemer in patients with intestinal failure due to the ultrarare disease MVID and the rare disease indication short bowel syndrome with intestinal failure (SBS-IF) in the United States, European Union, and/or Middle East/North Africa regions under appropriate regulatory approvals in each of these geographies.

As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, the initial proof-of-concept results of the ongoing IIT of a novel crofelemer powder formulation for oral solution in Abu Dhabi in the United Arab Emirates show that crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in the first participating MVID patient by up to 27% and in the first participating SBS-IF patient by up to 12.5%. An abstract describing the initial results of this trial has been accepted for presentation at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place November 5-8, 2025 in Chicago.

Additional proof-of-concept results from IITs of crofelemer for MVID and SBS-IF are expected later in 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. Data from both above-referenced placebo-controlled clinical studies is expected in 2026.

In accordance with the guidelines of specific European Union countries, published data from clinical investigations could support reimbursed early patient access to crofelemer for these debilitating conditions in 2026 while the company pursues approval of crofelemer for MVID and SBS-IF from the European Medicines Agency (EMA) and the FDA. Participation in early access programs, which do not exist in the U.S., provides an opportunity for reimbursement while impacting the morbidity and high cost of care for these chronic unmet needs. Additionally, the company expects that if even just a very small number of MVID patients show benefit with crofelemer, this may potentially allow expedited regulatory pathways in the U.S. and other regions, including qualifying crofelemer for participation in PRIME, an EMA program providing enhanced interaction and early dialogue with drug developers of novel medicines targeting unmet medical needs, and in the FDA’s Breakthrough Therapies program.

Patients with MVID and SBS-IF suffer from devastating diarrhea and dehydration caused by these debilitating, lifelong conditions. These patients are frequently on TPN for as long as 20 hours a day, seven days a week – and TPN carries a significant risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay. There are no approved drug treatments for MVID, an ultrarare pediatric disease with an estimated prevalence of about 200 patients worldwide. Short bowel syndrome (SBS) affects approximately 10,000 to 20,000 people in the U.S., according to the Crohn’s & Colitis Foundation, and it is estimated that the population of SBS patients in Europe is approximately the same size.

About Crofelemer
Crofelemer is a botanical (plant-based) drug extracted and purified from the red bark sap, also referred to as “dragon’s blood,” of the medicinal Croton lechleri tree in the Amazon Rainforest. Jaguar family company Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases.

For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that additional proof-of-concept results from IITs of crofelemer for MVID and SBS-IF will be available later in 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs, Jaguar’s expectation that data from both above-referenced placebo-controlled clinical studies will be available in 2026, Jaguar’s expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations could support reimbursed early patient access to crofelemer for MVID and SBS-IF in 2026 while the company pursues approval of crofelemer for MVID and SBS-IF from the EMA and the FDA, and Jaguar’s expectation that, if even just a very small number of MVID patients show benefit with crofelemer, this may potentially allow expedited regulatory pathways in the U.S. and other regions, including qualifying crofelemer for participation in the EMA’s PRIME program and the FDA’s Breakthrough Therapies program. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

CONTACT:
hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Acquisition advances value-based specialty care delivery by bringing predictive AI and precision patient-specialist matching into Switchboard’s specialty care platform

BOISE, ID AND NEW YORK CITY, NY / ACCESS Newswire / September 30, 2025 / Switchboard Health, creators of a digital health platform connecting patients with high-value specialty care, today announced the acquisition of Conduce Health, an AI-driven solution for personalized multispecialty care. The acquisition will combine Switchboard’s EMR-integrated software and virtual care network with Conduce’s predictive analytics and clinical decision support technology to match patients with the best-fit specialists.

Founded in 2023 by an experienced team of health tech entrepreneurs and physicians and backed by AlleyCorp, Conduce developed an AI platform that makes specialty care proactive, predictive, and personalized. Its software empowers clinical teams to refer patients to optimal specialists based on nuanced clinical and personal variables.

Through this acquisition, Switchboard Health will integrate Conduce’s advanced AI capabilities – including predictive models for disease progression, urgent medical needs, and precision patient-specialist matching – into its referral management, care navigation, and virtual care capabilities. These enhancements will enable Switchboard’s provider and health plan clients to even more effectively connect patients to high-value specialists. Key Conduce team members will also join Switchboard.

“This acquisition squarely fits our mission to transform specialty care,” said Derek Baird, CEO and co-founder of Switchboard Health. “The AI capabilities, expertise, and talent from Conduce will accelerate our progress in administering value-based specialty care models.”

“We founded Conduce to ensure patients receive personalized, multispecialty care the first time, every time,” said Najib Jai, MD, co-founder and CEO of Conduce Health. “We’re excited to see Switchboard integrate Conduce’s technology into its referral and care navigation workflows to advance that mission and deliver high-value specialty care at scale.”

“We have always believed Conduce’s AI-first approach could dramatically improve specialty care delivery,” said Jeff De Flavio, MD, Conduce Board Chair and AlleyCorp Entrepreneur in Residence. “We look forward to seeing the outcomes from pairing Conduce technology and key team members with Switchboard’s platform, value-based specialty care frameworks, and growing client base.”

About Switchboard Health
Switchboard Health helps providers, health plans, and employers deliver high-value specialty care services. Our software platform and national specialty care network deliver improved access, reduced costs, and much-needed support to patients seeking care. For more information, visit www.switchboardhealth.com

About Conduce Health
Conduce provides AI-powered tools risk bearing entities, hospital systems, and payers need to deliver value-based specialty care. Our novel approach incentivizes value-based alignment, facilitates care coordination, and ensures timely access to high-quality personalized, and affordable specialty care. Learn more at www.conducehealth.com.

MEDIA CONTACT:

Jessica Cohen
Aria Marketing for Switchboard Health
jcohen@ariamarketing.com
617.785.9579

SOURCE: Switchboard Health

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / September 30, 2025 / Avel eCare has been named among the Top Telemedicine Services of 2025 by Healthcare Business Review. The recognition highlights Avel’s role in setting a new standard for virtual, system-wide care, expanding access to high-quality healthcare in rural, urban, and underserved communities nationwide.

According to Healthcare Business Review, companies chosen for this prestigious list have “demonstrated outstanding capabilities in their respective industries, earning their place at the top. Renowned for their cutting-edge solutions, services, and exceptional customer support, they stand out in their fields after receiving numerous nominations. A panel of C-level executives, industry experts, and our editorial board conducted a comprehensive evaluation to select the top companies.”

With more than 30 years of telemedicine leadership, Avel eCare delivers an integrated system of care that spans emergency, behavioral health, hospitalist, pharmacy, specialty clinic, ICU, and more. By connecting hospitals, clinics, schools, EMS providers, and long-term care facilities to a team of board-certified physicians, nurses, and specialists, Avel provides reliable care that improves outcomes, reduces unnecessary transfers, and strengthens local health systems.

“This recognition reflects the tireless dedication of our team and our partners nationwide,” said Doug Duskin, CEO of Avel eCare. “From critical access hospitals to large health systems, our mission has always been the same: to ensure that every patient, no matter their location, has timely access to the highest level of care. Being honored as a top telemedicine service validates that vision.”

Avel eCare’s innovative approach has been proven to:

• Improve quality metrics such as reduced ICU length of stay and faster emergency department throughput

• Provide financial value by alleviating staffing shortages and reducing reliance on costly locum coverage

• Strengthen recruitment and retention by supporting bedside teams with 24/7 expertise

As demand for telehealth accelerates-with the global telehealth market projected to reach $1.18 trillion by 2032 according to BioSpace.com (https://www.biospace.com/telehealth-market-poised-to-surge-usd-1-186-59-billion-by-2032)- Avel continues to lead the way with scalable, reliable solutions that bring stability and innovation to healthcare delivery.

About Avel eCare
Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire

Historical report outlines a 3.4 km by 400-800 m corridor, high-grade channel samples up to ~170 g/t Au, and broad drill intercepts that remain untested by modern exploration technologies.

VANCOUVER, BC / ACCESS Newswire / September 30, 2025 / ESGold Corp. (“ESGold” or the “Company”) (CSE:ESAU)(OTCQB:ESAUF)(FSE:Z7D) is pleased to outline the prospective potential of a concession in Colombia’s Bolívar region, informed by historical NI 43-101 data and prior operator disclosures. The Bolívar district represents one of South America’s most prolific artisanal gold-producing regions, with historical work pointing to the scale, grade, and structural complexity consistent with a major mineralized system.

Historical Highlights (La Pantera, Bolívar – NI 43-101, July 25, 2018*)

• Large mineralized footprint: Zone No. 6, the most important structural corridor identified, measures approximately 3.4 km in strike length and 400-800 m in width. Multiple additional zones of mineralization occur across the 1,734-hectare concession.

• Widespread artisanal production: Hundreds of small-scale workings exploit saprolite and hard rock, with historical recoveries limited by rudimentary gravity methods – tailings still carry recoverable gold.

• High-grade samples: Underground channel sampling at Mina Bulla returned assays up to ~170 g/t Au, while saprolite “head” grades averaged ~1 g/t Au in places.

• Historical drilling: 19 holes (~4,180 m) at Los Matos reported broad, lower-grade intercepts (0.4-0.6 g/t Au over tens of metres), suggesting vein clusters and stockwork-style mineralization at depth.

• Untested depth potential: No systematic geophysics or modern drilling has tested below ~200 m, leaving deeper intrusive-related mineralization untested.

Regional and Historical Context

The Bolívar region, specifically the Serranía de San Lucas belt, has long been recognized for its gold endowment. Prior operator Origin Gold outlined in 2018 that the concession contained multiple mineralized zones, highlighting Zone No. 6 as the priority target. Despite pervasive artisanal mining and encouraging high-grade samples, the property remained underexplored, with no systematic geophysics, trenching, or follow-up drilling to test the system’s scale.

ESGold’s Strategy: Validate, Cash Flow, Discover

ESGold intends to approach Colombia the same way it has built Montauban in Quebec:

1. Validation First – Confirmatory sampling, QA/QC, and structural mapping to verify historical results and assess the scale of Zone No. 6 and surrounding targets.

2. Cash Flow Pathways – Evaluate tailings and near-surface material for clean reprocessing potential, creating early-stage cash flow to fund systematic exploration.

3. Systematic Exploration – Apply modern geophysics (including ANT imaging), trenching, and drilling to target both shallow and deeper mineralized zones across multiple corridors.

CEO Commentary

Gordon Robb, CEO of ESGold, stated:
“What excites us about Bolívar is the combination of scale, grade, and under exploration. Historical work shows high-grade channel samples in active workings, broad mineralized intercepts from earlier drilling, and a structural corridor more than three kilometers long that has never been tested with modern exploration tools. Add to that the extensive artisanal mining, which demonstrates the persistence of gold across the district, and it’s clear this is a system with exceptional potential. Our team is eager to validate the data and, if confirmed, advance a disciplined program that leverages our cash-flow-first model while unlocking what could be a district-scale gold discovery.”

Why This Matters to Investors

The Bolívar concession highlights ESGold’s ability to scale its dual-track model beyond Quebec:

• Large-scale footprint with multiple mineralized zones, including Zone No. 6, measuring 3.4 km by 400-800 m.

• High-grade potential with channel samples up to ~170 g/t Au, complemented by broad drill intercepts at lower grades.

• Extensive artisanal mining provides real-world validation of the system’s gold endowment.

• Replication of Montauban model: low-capex, cash flow-first development funding systematic exploration, with reduced dilution.

Qualified Person Statement
The technical content of this news release has been reviewed and approved by André Gauthier, P.Geo., a Director of ESGold and a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Sampling described herein was conducted for due-diligence screening; independent verification, QA/QC, and systematic work remain outstanding. No mineral resources or reserves are declared.

Disclaimer
*The technical information presented herein is historical in nature, derived from reports prepared for previous operators, – specifically the July 25th, 2018, NI43-101 Technical Report on the Pantera Gold Property by Pierre O’Dowd Pro. Geologist and Qualified Person – and should not be relied upon as current. ESGold has not completed the work necessary to independently verify these results, and a Qualified Person for ESGold has not done sufficient work to classify any historical estimate as current mineral resources or reserves. ESGold is not treating the historical information as current, and no mineral resources or reserves have been defined on the property at this time. Any future exploration, validation, or development work will be required to confirm the accuracy of the historical data before it can be considered reliable or used to support economic analysis.

About ESGold Corp.
ESGold Corp. (CSE:ESAU)(OTCQB:ESAUF)(FSE:Z7D) is a fully permitted, pre-production gold and silver mining company at the forefront of scalable clean mining and exploration innovation. With proven expertise in Quebec, the Company is advancing its Montauban Gold-Silver Project toward near-term production while unlocking long-term value through strategic redevelopment, modern discovery tools, and sustainable resource recovery. Montauban, located 80 km west of Quebec City, represents a blueprint for cash-flow-generating legacy site redevelopment across North America.

For more information, please contact ESGold Corp. at +1-888-370-1059 or visit esgold.com for additional resources, including a French version of this press release, past news releases, a 3D model of the Montauban processing plant, media interviews, and opinion-editorial pieces.

Stay connected by following us on X (formerly Twitter), LinkedIn, and joining our Telegram channel.

For further information or to connect directly, please reach out to Gordon Robb, CEO of ESGold Corp. at gordon@esgold.com or call 250-217-2321.

On behalf of the Board of Directors
ESGold Corp.
Paul Mastantuono
Chairman & COO
info@esgold.com
+1-888-370-1059

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements regarding future exploration, potential mineralization, production, cash flow, and growth strategy. Forward-looking information is based on reasonable assumptions believed to be current but involves known and unknown risks and uncertainties that may cause actual results to differ materially. Technical information relating to the Bolívar concession is historical in nature and has not been independently verified by ESGold. The Company has not completed the work necessary to treat any historical estimate as current and is not treating it as such. Readers are cautioned not to place undue reliance on such information. ESGold disclaims any obligation to update or revise forward-looking information except as required by law

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

SOURCE: ESGold Corp

View the original press release on ACCESS Newswire

Accelerates delivery of U.S.-made, defense-grade drones starting at an $800 price point, strengthening the domestic ecosystem

ORLANDO, FLORIDA / ACCESS Newswire / September 30, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a leading provider of high-performance drone components, today announced a $12.8 million order for components supplying Strategic Logix’s Rapid Reconfigurable Systems Line (RRSL). The order reflects the growing demand for NDAA-compliant unmanned aerial vehicle (UAV) solutions that can be fielded at scale to meet operational needs.

Unusual Machines is the primary supplier of NDAA-compliant components, including its BLUE UAS listed Aura Analog Camera, Aura VTX, Brave Flight Controller, and Brave ESC for the RRSL line. The RRSL-developed by Strategic Logix-is an interoperable UAV platform with configurations starting at $800, including manual, autonomous, and fiber-enabled options. The order covers more than 160,000 Unusual Machines-manufactured components, including ground control systems, highlighting both the demand scale and the company’s central role in enabling production.

“Our mission is clear-get U.S.-made innovation into warfighters’ hands faster,” said Jeremy Schnipke, CEO of Strategic Logix. “The RRSL is more than a product line-it’s a foundation for partnership. By working alongside Unusual Machines and a coalition that includes defense leaders, we can move with speed today while building the framework for deeper government relationships.”

Production and deliveries are scheduled to begin in the fourth quarter, reflecting careful planning and a rigorous approach to defense requirements. The order also signals the growing demand for low-cost, adaptable drones.

“We’ve been deliberate-maintaining the discipline and flexibility necessary to scale with the industry,” said Stacy Wright, EVP of Revenue at Unusual Machines. “That foundation lets us execute on short timelines with reliability as demand develops. Strategic Logix’s extensive track record of delivering for defense programs aligns perfectly with our role as a reliable link in the U.S.-built supply chain for drone components.”

Safe Harbor Statement

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the timing of when we will begin deliveries of the drone components and our ability to execute on short timelines. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The results expected by some or all of these forward-looking statements may not occur. Factors that affect our ability to achieve these results include unexpected issues that may arise from the opening of our new Orlando manufacturing facility, potential supply chain issues, , and the Risk Factors contained in our Form 10-Q for the period ended June 30, 2025, in our Prospectus Supplement dated September 2, 2025 and in our Form 10-K for the year ended December 31, 2024. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Any forward-looking statement made by us herein speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

About Strategic Logix

Strategic Logix is a U.S.-based defense innovation and procurement company that leads a coalition of more than 140 small businesses whose shared mission is to strengthen U.S. defense manufacturing and deliver low-cost, high-impact solutions directly to the modern warfighter. Founded to accelerate development and acquisitions, the company has evolved into a prime vendor of interoperable unmanned systems and modernization technologies, including its flagship Rapid Reconfigurable Systems Line (RRSL). With a proven track record in transformation, modernization, and innovation, Strategic Logix brings speed, flexibility, and trusted execution to the Department of Defense and allied partners.

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit www.unusualmachines.com.

Investor Contact:

CS Investor Relations
investors@unusualmachines.com

Media Contact:

media@unusualmachines.com

SOURCE: Unusual Machines

View the original press release on ACCESS Newswire

Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage – NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections

SHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2025 with the Securities and Exchange Commission (SEC) on Monday, September 29, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925094527/nnvc-20250630x10k.htm).

In the fiscal year 2025, we have achieved a substantial level of accomplishments. We have focused on evaluating the broad spectrum of antiviral activity of NV- 387.

We believe that NV-387 is on its way to become a revolutionary antiviral therapy that could be prescribed for practically any respiratory viral infection without first testing for the causative virus, just as broad-spectrum antibiotics can be prescribed even before testing for the causative bacteria. This “emperic therapy” approach would enable immediate treatment and thus improve effectiveness; it is well known that antiviral treatments are most effective when given early.

NV-387 would play in a market size of well over $20 Billion as a dominant player, if approved for such emperic therapy of viral ARI/SARI.

To this end, we have proposed a novel adaptive, Phase II clinical trial for the evaluation of NV-387 as a treatment for Viral Acute/Severe Acute Respiratory Infections (V-ARI, V-SARI) towards this goal. A preliminary clinical protocol for this complex trial has been developed.

At present, we are fully engaged in completing the Clinical Trial Application (CTA) for a Phase II clinical trial of NV-387 for the treatment of MPox disease in Africa. MPox continues to spread and surge in African countries and is endemic in the Democratic Republic of Congo (DRC) and neighboring countries. Due to this, African CDC has continued its declaration of Public Health Emergency of Continental Security (PHECS), initiated in August 2024, as of September, 2025. We have already obtained a preliminary approval for our clinical trial protocol for this clinical trial from the regulatory agency in charge, namely ACOREP in DRC.

We plan on leveraging the MPox studies towards approval of NV-387 as a treatment of Smallpox under the US FDA “Animal Rule”. The US agency BARDA has programs to support such development if NV-387 qualifies.

A potential acquisition of NV-387 for Smallpox under the US Strategic National Stockpile (US-SNS) if approved could be worth of the order of $1 billion over five years. We believe (i) NV-387 for treatment of MPox, (ii) NV-387 for the treatment of Smallpox, and (iii) NV-387 for the treatment of Measles, would be separately eligible for Orphan Drug Designation (ODD) by the US FDA. An ODD carries several benefits. Certain FDA fees would be waived. Up to seven years of market exclusivity would become available. There are also research and development tax benefits. In addition, some of these programs may be eligible for issuance of a tradable “Priority Review Voucher” (PRV) upon drug approval. A PRV if issued to us would in itself be a revenue generator with a value of over $150 million.

Smallpox is a bioterrorism threat. Two drugs, namely, tecovirimat and brincidofovir were approved in the USA for Smallpox under the FDA “Animal Rule” and have been acquired in the US-SNS. Both of these drugs have limitations. Therefore, the US agency BARDA is searching for a new drug. We believe NV-387 matches their requirements.

MPox Clade II is endemic in the USA and some European countries. MPox Clade Ia and Ib are more severe strains than Clade IIa or IIb, and are spreading in Africa. Clade Ia/Ib strains could break out of Africa globally and thereby cause severe pandemics. MPox is a much less severe cousin of Smallpox when compared in terms of the pathogenic effects and case fatality rates of the virus.

There is no drug for treatment of MPox at present. Tecovirimat failed in clinical trials for the treatment of MPox ^[1], ^[2]. Brincidofovir entered clinical trials for MPox in January, 2025, and interim results were anticipated in Q1 2025, according to the press release by Africa CDC ^[3]. The current status of this brincidofovir for MPox clinical trial is not publicly known ^[4] . Brincidofovir carries a black box warning due to increased mortality rates in another indication, causes elevation of liver damage-related markers, is a carcinogen, may cause embryonic or fetal harm, and may irreversibly impair fertility, according to its prescribing information ^[5], limiting its applicability.

Thus we believe NV-387 has a wide opportunity as a treatment of MPox, which can be currently estimated to be a market size approaching $1 Billion in African region alone.

We reported that, as of June 30, 2025, we had cash and cash equivalent current assets balance of approximately $1.67 Million. In addition, we reported approximately $6.83 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT, where we manufacture our clinical trial drug substance and drug products, thus producing substantial savings as compared to working with an external manufacturer (CDMO). The total current liabilities were approximately $1.31 Million. In comparison, as of June 30, 2024, we had cash and cash equivalent balance of approximately $4.97 Million, P&E assets of approximately $7.5 Million (after depreciation), and total current liabilities of approximately $1.36 Million.

The net cash utilized in the reported period for operating activities was approximately $8.48 million, which includes continuing expenditures for completion of the Phase Ia/Ib clinical trial of NV-387 in India, and R&D and preparatory work including cGMP manufacture of the drug substance for the Phase II clinical trial of NV-387 for treatment of MPox in Africa.

We raised approximately $5.3 million in net cash from financing activities, which comprised of an “At-the-Market” offering in an ATM Agreement with D. Boral Capital.

Subsequent to the reported period, we have raised approximately $1 million additional under the said ATM. Further, our founder, Dr. Anil Diwan has provided a line of credit (LOC) of $3 million to the Company. We have not yet drawn on the LOC. As such, we reported that we do not have sufficient funding in hand as of now to continue operations through September 30, 2026, for our planned objectives. As a result substantial doubt exists about the Company’s ability to continue as a going concern, as evaluated based on applicable guidelines. We are actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to our plan. We believe that the Company has on-going access to the capital markets including the “At-The-Market” (ATM) agreement that became active around April 5, 2024. We have previously adjusted our objectives and development plans on the basis of available resources and we will continue to do so.

This year, we have re-calibrated our priorities to seek opportunities with early fruition and lower cost compared to going after the longer horizon opportunities such as pediatric RSV treatment. We note that the Phase II clinical trial evaluating NV-387 for V-ARI/V-SARI will provide us with required information to move further into a Phase III for pediatric RSV approval.

We have several important milestones in the new year:

Completion and submission of the Phase I Clinical Study Report to the Indian regulatory Agency.

Filing of the Phase II Clinical Trial Application for the evaluation of NV-387 as a treatment for MPox to ACOREP in DRC, its Approval by the regulator, Commissioning of the clinical trial, and Interim Results.

Filing of Orphan Drug Designation applications to the US FDA as cited above, and their anticipated approval.

Filing of a pre-IND with the US FDA towards NV-387 for Smallpox treatment under the “Animal Rule”.

Filing of an IND with the US FDA towards evaluation of NV-387 as a Smallpox treatment leading to registration.

Filing of the Phase II Clinical Trial Application for the evaluation of NV-387 as a treatment for Viral Respiratory Infections in India, its Approval by the regulator, and Commissioning of the clinical trial, and Interim Results.

As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity-based funding.

We believe the Company has a bright future. Our Phase II clinical stage drug NV-387 has completed Phase I clinical trial with the successful results that there were no drop-outs, and there were no reported adverse events, both of which clearly indicate excellent safety and tolerability in humans. NV-387, as mentioned above, is likely to become a revolutionary broad-spectrum antiviral therapeutic, that could change how we treat viral infections forever. In addition, the Company has developed a pan-Herpesvirus drug, NV-HHV-1. Its skin cream formulation for the treatment of Shingles rash, Chickenpox, HSV-1 Cold Sores, and HSV-2 Genital Ulcers, has completed certain IND-enabling non-clinical studies. NV-HHV-1 has demonstrated effectiveness in a human skin model of VZV infection (Varicella-Zoster-Virus, which causes Chickenpox and Shingles). A systemic form of the herpesvirus drug is in development. The Company has also developed an anti-HIV drug, NV-HHV-1, which the HIV viruses would not be able to escape despite rapid virus evolution. NV-HHV-1 has demonstrated strong effectiveness superior to triple-drug combination HAART therapy in a humanized animal model of HIV infection.

The Company’s technology is based on mimicking the host-side binding sites that the virus uses which remain the same despite several and extensive changes in the virus. We design and make chemical mimics of these sites to create virus-binding ligands that we attach to a base polymer. This makes the drug look like a cell membrane to the virus. The nanoviricide drug is thus designed to fool the virus into entering the nanoviricide drug micelle and uncoating itself by using the virus’s own smarts against it.

We believe viruses would not be able to escape nanoviricide drugs because of this design. In contrast, viruses readily escape vaccines, antibodies, and most of the small chemical drugs.

Oral NV-387 was found to be superior to the three known drugs oseltamivir (Tamiflu®, Roche), peramivir (injection, Rapivab®, BioCryst), as well as baloxavir (Xofluza®, Shionogi/Roche) in a lethal lung infection animal model of Influenza.

Oral NV-387 was found to cure lethal lung RSV infection in an animal model. There is no current approved drug for treating RSV infection.

Previously, NV-387 given both orally and as I.V. injections was found to be substantially superior to remdesivir (injection, Gilead) in a lethal lung infection animal model for COVID-19.

Oral NV-387 was found to be equivalent to or superior than tecovirimat (TPOXX®, SIGA) in two different lethal animal models of orthopoxvirus diseases. One of these models simulated skin infection which is the primary route of MPox Clade II infections. Another animal model simulated direct lung infection which is the likely route of Smallpox infection in case of bioterrorism.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

Kiosks will combine everyday banking with secure Bitcoin purchases, expanding access to digital currency in trusted retail locations

MIAMI, FL / ACCESS Newswire / September 30, 2025 / Athena Bitcoin Global (OTC PINK:ABIT) (“Athena” or the “Company”), the third largest global operator of Bitcoin kiosks and digital asset fintech solutions, today announced a strategic partnership with Cash Depot to integrate Athena’s Bitcoin purchase software into Cash Depot’s Bank in a Box kiosks.

This partnership will launch with select Bank in a Box kiosks, integrating Athena’s Bitcoin purchase software alongside traditional ATM services in convenience stores and retail locations. Retailers hosting these kiosks can expect to benefit from increased traffic and added revenue opportunities as Bitcoin adoption grows.

“At Athena, we’re committed to making Bitcoin more accessible through technology that prioritizes the customer experience and security,” said Matias Goldenhörn, CEO of Athena Bitcoin Global. “Partnering with Cash Depot not only brings Bitcoin purchasing capabilities to kiosks people already trust for everyday financial transactions, but it also expands Athena’s footprint into new retail locations, strengthening our ability to reach more customers where they are.”

Bank in a Box is Cash Depot’s all-in-one smart kiosk, combining ATM withdrawals, deposits, bill pay, and cash management services. Through this partnership, select kiosks in convenience stores and retail locations will now also enable secure, seamless Bitcoin purchases.

“Bank in a Box was designed to provide retailer hosts with a comprehensive financial services solution,” said Sean Burke, CEO of Cash Depot. “By adding Athena Bitcoin’s capabilities, we’re enhancing that value by offering customers modern, convenient ways to access digital currency and providing the choice to buy Bitcoin alongside traditional banking services.”

The service is now live, with both companies planning additional deployments as consumer demand for Bitcoin access continues to grow. Users can locate participating Bank in a Box kiosks via Athena Bitcoin’s ATM locator or Cash Depot’s website.

About Athena Bitcoin Global

Athena Bitcoin Global operates an international network of Athena Bitcoin kiosks, which are freestanding kiosks that permit customers to buy or sell Bitcoin in exchange for fiat currencies. The Company places its machines in convenience stores, shopping centers, and other easily accessible locations in thirty-three U.S. states and territories, and in four countries in Central and South America. Athena Bitcoin Global’s comprehensive fintech platform enables POS merchant payments powered by Athena Pay, and the Company provides safe, reliable, and personalized trading services through its Athena Plus services. To learn more, visit www.athenabitcoin.com or follow Athena Bitcoin Global on Twitter and LinkedIn.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to anticipated user adoption, expansion opportunities, and technology integration timelines. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market conditions, user demand, and regulatory considerations. Athena Bitcoin Global specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Rachele Andrejczak
Director of Marketing, Athena Bitcoin, Inc.
rachele@athenabitcoin.com
(786) 347-6242

SOURCE: Athena Bitcoin Global

View the original press release on ACCESS Newswire

New feature gives drivers faster, on-demand access to their earnings for everyday expenses.

BLOOMINGTON, MINNESOTA / ACCESS Newswire / September 30, 2025 / Dispatch, the technology leader in last-mile delivery, today announced Instant Pay in the Dispatch Driver App, enabling drivers to access their earnings immediately after completing deliveries. The new capability helps drivers cover time-sensitive expenses – like fuel, tolls, and everyday necessities – without waiting for standard payout cycles.

“With Instant Pay, we’re giving drivers more control over their cash flow so they can focus on doing great work,” said Joyce Schofield, VP of Product & UXD at Dispatch. “Drivers asked for faster access to earnings; we designed Instant Pay with them at the center, from the tap-simple experience to transparent terms.”

Meeting Driver Needs

Instant Pay delivers value to drivers in three key areas:

• Financial flexibility: Access earnings right after delivery completion, no waiting for cycle payouts.

• More control: Drivers choose when to transfer funds based on their needs and schedule.

• Competitive parity: Delivers the convenience drivers expect from modern gig platforms within the Dispatch ecosystem they trust.

The launch of Instant Pay builds on Dispatch’s mission to empower drivers with the tools and support they need to thrive in today’s fast-paced gig economy.

About Dispatch: Dispatch is redefining last-mile delivery for the modern business. As the premier B2B delivery platform, Dispatch empowers organizations with scalable, technology-driven solutions that streamline logistics, enhance visibility, and improve customer satisfaction. Through its robust delivery management software, seamless API integrations, and a reliable network of independent contractor drivers, Dispatch enables businesses of all sizes to simplify and optimize their last-mile operations.

Contact Information

Buse Kayar
busek@accessnewswire.com

Joyce Schofield
Dispatch VP of Product & UXD
(952) 444-5280

SOURCE: Dispatch

Related Images

View the original press release on ACCESS Newswire

ACE’s unique operational model and student-centric focus allow it to add staff, programs, partnerships and scholarships even as financial uncertainty forces layoffs and tuition hikes throughout higher education.  

INDIANAPOLIS, INDIANA / ACCESS Newswire / September 30, 2025 / As U.S. colleges and universities cut staff, eliminate programs and hike tuition in response to political and economic uncertainty, American College of Education (ACE) is expanding. ACE is investing in people, programs, and technology, demonstrating that its mission-aligned, efficiency-driven model can thrive even as most of the higher education sector struggles.

“At ACE, we constantly work to keep costs down while developing academic programs that generate real economic value in the workplace for our graduates,” said Geordie Hyland, president and CEO of ACE.

Founded in 2005, ACE is a national innovator providing quality, affordable and accredited online undergraduate, graduate and doctoral degrees. ACE is the third-highest conferrer of education master’s degrees in the United States¹, and its low tuition enables nearly nine out of 10 students to graduate debt-free².

Most U.S. higher education institutions accept federal Title IV student loans, which makes them vulnerable to changes in federal funding. ACE is virtually unique in that it does not accept federal Title IV student loans, avoiding the high overhead and bureaucratic expenses of administering the program.

That also allows the college to avoid uncertainty around federal spending that is forcing cutbacks and price increases across the sector: Renowned institutions including Cornell University and Duke University have announced layoffs, while public universities in Kansas, Michigan, Minnesota, Nebraska and Oklahoma have increased tuition significantly.

Instead, ACE can focus on maintaining low tuition and creating degree and certificate programs that appeal to students seeking career advancement.

“We are absolutely committed to transparency about how much an ACE degree will cost, which allows students to make the best decision for their future,” Hyland said. “With student debt approaching $2 trillion, our growth reflects a broader shift toward accessible, value-driven education.”

To support its growing student base, ACE is investing in the tools and infrastructure required for high-quality online learning. Upgrades in technology, platforms, and user experience are helping the college deliver a seamless and scalable educational model tailored for adult learners. In forgoing the costs associated with dormitories and athletic facilities, ACE can deliver essential academic services while passing the savings along to its students.

Those investments pay off in student success. ACE has an 85% graduation rate for all degree programs combined, significantly exceeding the national six-year completion rate of 62%. ACE students also receive a strong return on investment (ROI): According to a study by the consulting firm Lightcast, ACE students gain $19.20 in future earnings for every dollar of tuition, for a 120.7% annual return.

This performance and growth underscores ACE’s resilience and adaptability during a time of sector-wide instability. The college’s operating model, focus on transparency, and mission-driven approach continue to differentiate it from traditional institutions facing deep financial and operational strains.

For more information, please visit http://ace.edu/.

¹ nces.ed.gov/IPEDS/datacenter

² ACE internal research, March 2025

About American College of Education

American College of Education (ACE) is an accredited, fully online college specializing in high-quality, affordable programs in education, business, leadership, healthcare and nursing. Headquartered in Indianapolis, ACE offers more than 60 innovative and engaging programs for adult students to pursue a doctorate, specialist, master’s or bachelor’s degree, along with graduate-level certificate programs. In addition to being a leader in online education, ACE is a Certified B Corporation and part of a global movement to use the power of business to solve social and environmental problems.

SOURCE: American College of Education

Related Images

View the original press release on ACCESS Newswire